甲状旁腺功能减退症药物卡夫帕雷肽的中期数据显示，MBX飙升160%

2025-09-22 22:20

MBX Biosciences (NASDAQ:MBX) is up ~160% in Monday morning trading after posting phase 2 data on hypoparathyroidism candidate canvuparatide indicating it met its primary goal.
In the 12-week randomized portion of the trial, 63% of canvuparatide-treated patients met the prespecified primary composite endpoint, maintaining albumin-adjusted serum calcium levels in the normal range no conventional therapy (calcium and vitamin D supplements). For the placebo group, the figure was 31%.
In the open-label extension of the study, 79% of participants that received treatment gained responder status at six months.
No serious adverse events or deaths related to canvuparatide were reported.
If approved, canvuparatide would likely compete against Ascendis Pharma's (ASND) Yorvipath (palopegteriparatide). In March, AstraZeneca (AZN) released positive phase 3 results on its hypoparathyroidism asset, eneboparatide. Septerna (SEPN) also has a candidate in the IND-enabling stage.
Guggenheim, which rates MBX at buy, raised its price target to $84 from $44 on the news, saying that PTH is "poised to have the first once-weekly PTH replacement therapy.

More on MBX Biosciences